- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Gillian M. Russell
Insights 16 results
Client Alert
July 12, 2024
FDA Issues Updated Draft Guidance on Addressing Misinformation About Medical Devices and Prescription Drugs
Client Alert
April 25, 2024
FDA Updates Draft Guidance on Promotional Labeling and Advertising Considerations for Biological Reference Products and Biosimilars
Article · Source: The Legal 500
December 5, 2023
The Legal 500 Country Comparative Guides: United States Pharmaceutical Advertising
Client Alert
October 25, 2023
Beyond Reprints for Scientific Information on Unapproved Uses of Medical Products
Client Alert
August 10, 2023
FTC Revamps the “Guides Concerning the Use of Endorsements and Testimonials in Advertising”
Client Alert
June 30, 2023
FDA Finalizes Guidance on Presenting Quantitative Efficacy and Risk Information in DTC Promotion
Article · Source: Chambers & Partners
April 1, 2023
Chambers Global Practice Guide: Pharmaceutical Advertising 2023
Client Alert
January 23, 2023
2022 Year in Review: FDA Drug and Device Advertising and Promotion Enforcement
Article · Source: Chambers and Partners
March 21, 2022
Chambers Global Practice Guide: Pharmaceutical Advertising 2022
Client Alert
January 26, 2017
FDA Defends Its First Amendment Position in “Memorandum”
Client Alert
January 20, 2017
FDA Issues Draft Guidance Addressing Communications with Payors
Client Alert
January 19, 2017
FDA Takes Action in the Last Days of the Obama Administration to Clarify Some of Its Views on Off-Label Communications